lysosomal storage disorder

Two for two: Sanofi snares twin European nods for enzyme replacement therapies

Sanofi won European Commission approval for two therapies that treat rare enzyme deficiencies. Xenpoyzme is the first treatment for acid sphingomyelinase deficiency (ASMD) while Nexviadyme is a successor to a blockbuster Sanofi drug for Pompe disease.

By Frank Vinluan

BioPharma, Startups

Gene therapy startup Lacerta Therapeutics raises $30M in equity financing from Sarepta

Sarepta Therapeutics gains rights to University of Florida-resident startup's programs for central nervous system diseases.

By Alaric DeArment

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.